Pyxis Oncology Inc. has announced the upcoming presentation of translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate $(ADC)$, at two major medical meetings. The data will be shared in two posters at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, and in six posters at the AACR-NCI-EORTC International Conference in Boston, Massachusetts. MICVO is designed to target extradomain-B of fibronectin (EDB+FN) and employs an extracellular-cleaving mechanism. The findings to be presented include MICVO's mechanism of action, which involves direct tumor cell killing, bystander effect, and immunogenic cell death, as well as its effects on tumor microenvironment remodeling and immune activation. Presentation materials will be made available on the company's website following the conclusion of each meeting.